KR102763559B1 - Composition for preventing, ameliorating or treating intestinal disease comprising Lysimachia christinae extract as effective component - Google Patents

Abstract

The present invention relates to a composition containing an extract of Gold Leaf as an effective ingredient for preventing, improving or treating intestinal diseases. Specifically, when an extract of Gold Leaf is administered to an animal model of colitis induced by DSS (dextran sulfate sodium), weight loss and colon length shortening caused by DSS are suppressed, and disease activity index (DAI) and intestinal permeability are reduced. Therefore, the composition can be very usefully used as a health functional food or medicine for preventing, improving or treating intestinal diseases.

Description

Composition for preventing, ameliorating or treating intestinal disease comprising Lysimachia christinae extract as effective component

The present invention relates to a composition for preventing, improving or treating intestinal diseases, comprising an extract of Geumjeoncho as an effective ingredient.

Intestinal diseases are common diseases in modern people that cause digestive problems and are accompanied by abdominal pain and are caused by various reasons. They are mainly divided into inflammatory bowel disease and irritable bowel syndrome.

Ulcerative colitis or Crohn's disease is an inflammatory bowel disease (IBD) of unknown cause, and is a chronic, intractable disease that repeats healing and relapse. It has been suggested that environmental factors such as diet, as well as genetic factors and immune abnormalities, are involved in the etiology of these diseases, but the cause is still unknown. Ulcerative colitis is an inflammatory disease in which ulcers or lesions are continuously formed on the mucous membrane of the large intestine, causing bloody stool, bloody stool, diarrhea, and abdominal pain, and in severe cases, systemic symptoms such as fever, weight loss, and anemia. In addition, Crohn's disease is characterized by the discontinuous occurrence of lesions such as inflammation or ulcers in any part of the digestive tract from the mouth to the anus, and in addition to abdominal pain, diarrhea, and bloody stool, in severe cases, fever, bloody stool, weight loss, general malaise, and anemia.

Previously, the incidence of these inflammatory bowel diseases was known to be high in the West, but recently, the number of patients has been rapidly increasing in Korea due to changes in lifestyle habits such as eating habits. However, there is no established fundamental treatment method because the cause is unclear. Therefore, the current treatment does not aim for a complete cure, but aims to improve symptoms and maintain them for a long period of time. As drugs for this treatment, aminosalicylates, adrenal cortex steroids, and immunosuppressants are mainly used, but their side effects present significant clinical problems. For example, the side effects of salazosulfapyridine, which is frequently used as an aminosalicylates, have been reported to include nausea, vomiting, loss of appetite, rash, headache, liver damage, leukopenia, abnormal red blood cells, proteinuria, and diarrhea. In addition, adrenal corticosteroids are generally used as oral administration of prednisolone, enema, suppository, intravenous injection, etc., but there are side effects such as gastric ulcers and femoral head necrosis due to long-term use. However, since discontinuation of medication causes recurrence of symptoms, these drugs cannot be used continuously.

Irritable bowel syndrome (IBS) is a chronic disease that causes abdominal discomfort and pain, such as abdominal distension, for a long time without an underlying cause, and changes in bowel habits, such as diarrhea and constipation. The symptoms can also worsen due to psychological factors or stress. Depending on the symptoms, it is categorized into diarrhea-predominant, constipation-predominant, and pain-predominant types and treated with medication. Among patients in Korea, diarrhea accounts for 30.8%, constipation accounts for 24.6%, and alternating diarrhea and constipation accounts for 44.6%.

Pharmacotherapy for the treatment of irritable bowel syndrome can be divided into drugs that improve the overall symptoms of irritable bowel syndrome and drugs for a single symptom. Smooth muscle relaxants, antidepressants, and opioid agonists are used for abdominal pain, and fiber agents, laxatives, and 5-HT4 agonists are used for constipation-predominant irritable bowel syndrome, and antidiarrheal agents and 5-HT3 antagonists are used for diarrhea-predominant irritable bowel syndrome. However, since the use of existing 5-HT series drugs is limited due to side effects, drug therapy for irritable bowel syndrome is very limited to date, and the reliance on symptomatic treatment is high, which is unsatisfactory.

Meanwhile, Lysimachiae Herba is a medicinal herb that is the dried whole plant of Lysimachia christinae Hance of the Primrose family. In Korea, the whole plant of Glechoma hederacea L. of the Lamiaceae family is sometimes used as a substitute. In oriental medicine, it is known to have the effects of being spicy and slightly bitter and slightly cool in nature, clearing heat and eliminating dampness (clearing heat and eliminating dampness), eliminating damp-heat in the lower abdomen and eliminating stones, removing symptoms of urination that are clear and painful or dripping and not clearing easily (relieving pain), and reducing swelling in boils or wounds (reducing swelling).

As for prior art related to intestinal diseases, Korean Patent No. 128920 discloses a 'composition for treating and preventing intestinal diseases containing an extract of Phellodendron amurense leaf as an active ingredient', and Korean Patent Publication No. 2023-0111825 discloses a 'composition for preventing or treating intestinal diseases containing an extract of Terrestrial Herb as an active ingredient'. However, the 'composition for preventing, improving or treating intestinal diseases containing an extract of Geumjeoncho as an active ingredient' of the present invention has not been disclosed yet.

The present invention was derived from the above-mentioned needs, and the present invention provides a composition for preventing, improving or treating intestinal diseases, which contains an extract of Geumjeoncho as an effective ingredient, and specifically, the present invention was completed by confirming that when an extract of Geumjeoncho was administered to an animal model of colitis induced by DSS (dextran sulfate sodium), weight loss and colon length shortening caused by DSS were suppressed, and disease activity index (DAI) and intestinal permeability were reduced.

In order to solve the above problem, the present invention provides a health functional food composition for preventing or improving intestinal disease containing an extract of Geumjeoncho as an effective ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating intestinal diseases containing an extract of Geumjeoncho as an effective ingredient.

In addition, the present invention provides a feed additive for preventing or improving intestinal diseases containing an extract of Geumjeoncho as an effective ingredient.

In addition, the present invention provides a veterinary composition for preventing or treating intestinal diseases containing an extract of Geumjeoncho as an effective ingredient.

In addition, the present invention provides a herbal medicine composition for preventing or treating intestinal diseases containing an extract of Geumjeoncho as an effective ingredient.

The present invention relates to a composition containing an extract of Gold Leaf as an effective ingredient for preventing, improving or treating intestinal diseases. Specifically, when an extract of Gold Leaf is administered to an animal model of colitis induced by DSS (dextran sulfate sodium), weight loss and colon length shortening caused by DSS are suppressed, and disease activity index (DAI) and intestinal permeability are reduced.

Figure 1 shows the results of confirming cell survival rate when Caco-2 cells were treated with luteinizing chive extract (LCH) and interleukin-6 (IL-6).
Figure 2 shows the results of measuring dextran permeability when Caco-2 cells were treated with luteinizing chive (LCH) and interleukin-6 (IL-6). ### indicates that the dextran permeability of the IL-6 only treatment group significantly increased compared to the untreated control group, and p<0.001. *** indicates that the dextran permeability of the 25 and 50 mg/㎖ luteinizing chive (LCH) and IL-6 treatment groups significantly decreased compared to the IL-6 only treatment group, and p<0.001.
Figure 3 is a schematic diagram of an experiment to confirm the improvement efficacy of administering a gold leaf extract to a mouse model of colitis induced by 5% DSS (dextran sulfate sodium).
Figure 4 shows the results of confirming the change in body weight due to DSS administration when the extract of the present invention was administered to a colitis mouse model induced with 5% DSS (dextran sulfate sodium). ### indicates that the body weight of the colitis-induced group by DSS treatment significantly decreased compared to the normal group that was not treated with anything, and p<0.001. * and ** indicate that the body weight of the colitis-induced group (LCHL, LCHH) and the positive control group (ASA) statistically significantly increased compared to the colitis-induced group (DSS). * indicates p<0.05, and ** indicates p<0.01.
FIG. 5 shows the results of confirming the change in the length of the large intestine when the extract of the present invention was administered to a mouse model of colitis induced with 5% DSS (dextran sulfate sodium). A is a photograph of the large intestine extracted from each mouse group, and B is a graph showing the measured length of the large intestine. NOR is a normal group that was not treated with anything, DSS is a group induced with colitis by DSS treatment, DSS+LCHL is a group administered with DSS and the extract of the large intestine (100 mg/kg), DSS+LCHH is a group administered with DSS and the extract of the large intestine (200 mg/kg), and DSS+ASA is a positive control group administered with DSS and 5-ASA (5-aminosalicylic acid). ### indicates that the length of the large intestine of the group induced with colitis by DSS treatment was significantly reduced compared to the normal group that was not treated with anything, and p<0.001. ** indicates that the colon length of the group administered with the extract of the Korean angelica tree and the positive control group significantly increased compared to the group induced with colitis by DSS treatment, p<0.01.
Figure 6 shows the results of confirming the change in the disease activity index (DAI) due to DSS administration when the extract of the present invention was administered to a colitis mouse model induced with 5% DSS (dextran sulfate sodium). ### indicates that the disease activity index on the 8th day of the colitis-induced group (DSS) by DSS treatment was significantly increased compared to the normal group (NOR) that was not treated with anything, and p<0.001. * and *** indicate that the disease activity index on the 8th day of the colitis-induced group (DSS) administered with the extract of the gold dandelion (LCHL, LCHH) and the positive control group (ASA) was statistically significantly decreased compared to the colitis-induced group (DSS), and * indicates p<0.05 and *** indicates p<0.001.
Figure 7 shows the results of measuring intestinal dextran permeability when the extract of the present invention was administered to a DSS (dextran sulfate sodium)-induced colitis mouse model. ### indicates that the dextran permeability of the colitis-induced group (DSS) treated with DSS was significantly increased compared to the normal group (NOR) that was not treated at all, and p<0.001. ** indicates that the dextran permeability of the groups administered with the extract of the gold dandelion (LCHL, LCHH) and the positive control group (ASA) was statistically significantly decreased compared to the colitis-induced group (DSS), and p<0.01.
Figure 8 is an endoscope photograph of a colon lesion when the extract of the present invention was administered to a mouse model of colitis induced by 5% DSS (dextran sulfate sodium).

In order to achieve the purpose of the present invention, the present invention provides a health functional food composition for preventing or improving intestinal diseases containing an extract of Lysimachia christinae as an effective ingredient.

The above-mentioned gold leaf extract may be manufactured by a method including, but not limited to, the following steps:

1) A step of extracting by adding an extraction solvent to the gold leaf;

2) a step of filtering the extract of step 1); and

3) A step of producing an extract by concentrating and drying the filtered extract of step 2) under reduced pressure.

In the above step 1), the extraction solvent is preferably water, a lower alcohol of C ₁ to C ₄ , or a mixture thereof, more preferably ethanol, but is not limited thereto.

In the above manufacturing method, the extraction of gold leaf may utilize all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. The reduced pressure concentration in step 3) above is preferably performed using a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably performed using reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.

The above intestinal disease may be, but is not limited to, inflammatory bowel disease or irritable bowel syndrome. The above inflammatory bowel disease may be, but is not limited to, any one selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis.

The above composition is preferably prepared in any one dosage form selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage, but is not limited thereto.

When the health functional food composition of the present invention is used as a food additive, the extract of the gold leaf plant may be added as it is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The amount of the effective ingredient may be appropriately determined depending on the purpose of use (prevention or improvement). In general, when manufacturing a food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, to the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the effective ingredient may be used in an amount greater than the above range. There is no particular limitation on the type of the food. Examples of foods to which the extract may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and include all health functional foods in the conventional sense.

When the composition of the present invention is used as a health beverage, it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. The natural carbohydrates mentioned above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclotensin, and sugar alcohols such as xylitol, sorbitol and erythritol. As a sweetener, a natural sweetener such as thaumatin and stevia extract, or a synthetic sweetener such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 g of the composition of the present invention. The composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These components may be used independently or in mixtures. The ratio of these additives is not particularly important, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

In addition, the present invention provides a pharmaceutical composition for preventing or treating intestinal diseases containing an extract of Lysimachia christinae as an effective ingredient.

The above intestinal diseases are as described above.

The composition of the present invention is preferably prepared in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols, but is not limited thereto.

The composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-mentioned effective ingredient, and may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include capsules, powders, granules, tablets, pills, etc., and such solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, emulsions, syrups, and aerosols, and in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin. For parenteral administration, it is desirable to select external skin application or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine epidural, or intracerebrovascular injection methods.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, the "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the level of the effective amount can be determined according to the type and severity of the patient's disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the excretion rate, the treatment period, the concurrently used drugs, and other factors well known in the medical field. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects by considering all of the above factors, and this can be easily determined by those skilled in the art.

The dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity, and the daily dosage is 0.01 to 2,000 mg/kg based on the amount of the extract of Geumjeoncho, preferably 30 to 500 mg/kg, and more preferably 50 to 300 mg/kg, and can be administered 1 to 6 times a day. The composition of the present invention can be used alone or in combination with methods using surgery, radiotherapy, hormone therapy, chemotherapy, and biological response modifiers.

In addition, the present invention provides a feed additive for preventing or improving intestinal diseases containing an extract of Lysimachia christinae as an effective ingredient.

The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. The term 'feed' in the present invention may mean any natural or artificial diet, meal, etc., or a component of the meal, which is suitable for animals to eat, ingest, and digest. The type of the feed is not particularly limited, and feed commonly used in the relevant technical field may be used. Non-limiting examples of the feed include plant feeds such as grains, roots, food processing by-products, algae, fibers, pharmaceutical by-products, fats, starches, meal, or grain by-products; animal feeds such as proteins, inorganic substances, fats, minerals, fats, single-cell proteins, zooplankton, or food. These may be used alone or in combination of two or more.

In addition, the present invention provides a veterinary composition for preventing or treating intestinal diseases containing an extract of Lysimachia christinae as an effective ingredient.

The veterinary composition of the present invention may further comprise suitable excipients and diluents according to conventional methods. Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxy benzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.

The veterinary composition according to the present invention may additionally contain fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, etc., and the veterinary composition according to the present invention may be formulated using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to an animal, and the formulation may be in the form of a powder, granule, tablet, capsule, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, suppository, sterile injectable solution, sterile external preparation, etc.

The effective amount of the veterinary composition according to the present invention can be appropriately selected depending on the individual animal. It can be determined based on factors including the severity of the disease or condition, the sensitivity to the effective ingredient of the present invention according to the age, weight, health status or sex of the individual, the route of administration, the period of administration, other compositions combined or used simultaneously with the composition, and other factors well known in the field of physiology or veterinary medicine.

In addition, the present invention provides a herbal medicine composition for preventing or treating intestinal diseases containing an extract of Lysimachia christinae as an effective ingredient.

The herbal medicine composition of the present invention means, but is not limited to, one manufactured according to a traditional Korean medical prescription.

Hereinafter, the present invention will be described in detail by examples. However, the following examples are only intended to illustrate the present invention, and the content of the present invention is not limited to the following examples.

<Materials and Methods>

1. Cytotoxicity

Caco-2 cells were cultured in 48-well cell culture plates at a density of 5 × 10 ⁴ cells/well and co-treated with the extract of gold mint and interleukin-6 (IL-6) for 24 h. Cytotoxicity was measured at 450 nm in a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA) using CCK-8 (Cell Counting Kit-8; Dojindo Molecular Technologies Inc., Rockville, MD, USA).

2. Measurement of inter-epithelial cell permeability

Caco-2 cells were cultured at a density of 1 × 10 ⁵ cells/insert on PET (polyethylene terephthalate) membrane inserts (0.4 μm pore, 0.33 cm ² ; Millipore), and fully differentiated. After co-treatment with gold mint extract and interleukin-6 (IL-6) for 24 h, FITC-dextran (1 mg/mL) was added to the insert using a non-absorbable FITC-dextran probe (FD-4), and after 1 h of culture, 100 μL of medium under the insert was placed into a 96-well plate, and the FITC fluorescence value (Excitation: 490 nm; Emission: 520 nm) was measured using a precision microplate reader.

3. Establishment of DSS-induced colitis animal model and sample treatment

Seven-week-old male C57/BL6 mice were purchased from Dooyeol Biotech Co., Ltd. (Seoul, Korea) and divided into five groups (n=10 per group): normal group without any treatment (NOR), colitis-induced group by 5% DSS treatment (DSS), group administered with 5% DSS and 100 mg/kg of the extract of Geumjeoncho (DSS+LCHL), group administered with 200 mg/kg of the extract of Geumjeoncho (DSS+LCHH), group administered with 100 mg/kg of the extract of Geumjeoncho (DSS+AS) and 5% DSS.

DSS (dextran sulfate sodium)-induced colitis mice were established by feeding 5% (w/v) DSS (MP Biomedicals, molecular weight 36,000–50,000) dissolved in drinking water to the mice for 5 days and then allowing them to drink DSS-free water for 3 days (Fig. 3). From the first day of DSS feeding, either the extract of Ligusticum officinalis (100 mg/kg, 200 mg/kg) or 5-ASA (100 mg/kg) was orally administered, and body weights were measured every day before administration. The colon length was measured and photographs were taken after the experiment was completed and the mice were sacrificed.

4. Disease activity index (DAI) assessment

During the experimental schedule, the body weight, stool condition, and severe bleeding of the mice were recorded daily to assess the severity (Table 1). The DAI was determined as the mean of the scores of [(body weight loss + stool condition + severe bleeding)/3].

Evaluation index for weight, stool condition and intestinal bleeding DAI score Weight loss(%) Stool condition Rectal bleeding 0 None Normal None 1 1-5 - - 2 5-10 Loose stools - 3 10-20 - - 4 >20 Diarrhea Gross bleeding

5. In vivo epithelial cell transmembrane permeability

On day 8 of the experiment, pericellular epithelial permeability was determined using non-absorbable FD-4 (FITC-conjugated 4-kD dextran). Mice were administered 60 mg/100 g FD-4 solution by gavage, and serum was collected after 4 h, and FD-4 content was measured at 490 nm excitation and 520 nm emission using a VERSAmax microplate reader.

6. Colonoscopy Analysis

On the 8th day of the experiment, high-resolution images of the colon of mice anesthetized with isoflurane were obtained using a mini-endoscopy with a visible light source (OLYMPUS, Tokyo, Japan, length 670 mm, diameter 2.8 mm).

7. Statistical processing

The data obtained in the present invention were expressed as the mean ± standard error, and statistical analysis was performed using the Student t-test, and calculated using a one-way analysis of variance accompanied by the Tukey test and Dunnett's test.

Manufacturing Example 1. Manufacturing of Gold Leaf Extract

1 kg of Goldenseal was placed in 15 ℓ of 70% (v/v) ethanol, and refluxed for 3 hours (heating mantle), filtered and soaked with qualitative filter paper (Whatman No. 4), concentrated under reduced pressure 10-fold with a rotary evaporator (EC-1020), and then freeze-dried (Ilshin Bio LP20).

Example 1. Confirmation of cytotoxicity of the extract of gold leaf

When Caco-2 cells were treated with the extract of the present invention at various concentrations, cell viability was measured.

As a result, as disclosed in Fig. 1, it was confirmed that the cell viability was high at all treatment concentrations of the extract of Geumjeoncho, indicating no cytotoxicity.

Example 2. Effect of the extract of the goldenrod on reducing the permeability between epithelial cells

When the extract of the present invention was treated at various concentrations in Caco-2 cells, the intercellular permeability was measured.

As a result, as disclosed in Fig. 2, the dextran permeability of the IL-6 only treated group significantly increased compared to the untreated control group, and in contrast, the dextran permeability of the group administered the extract of the gold ginseng of the present invention significantly decreased.

Example 3. Weight loss inhibition effect by administration of gold leaf extract

The change in body weight following administration of the extract of the present invention to a mouse model of colitis was observed.

As a result, as disclosed in Fig. 4, the body weight in the colitis-induced group (DSS) administered with DSS decreased compared to the normal group (NOR) that was not treated with anything, whereas the body weight that had been decreased by DSS administration increased in the groups administered with the extract of the present invention (LCHL, LCHH).

Example 4. Inhibitory effect of colon length reduction by administration of gold leaf extract

The change in colon length following administration of the extract of the present invention was observed in a mouse model of colitis.

As a result, as disclosed in Fig. 5, the length of the large intestine shortened by DSS administration was statistically significantly increased in the group administered with the extract of the Korean angelica tree.

Example 5. Effect of administration of extract of gold leaf on disease activity index (DAI) reduction

Changes in the disease activity index following administration of the extract of the present invention to a mouse model of colitis were observed.

As a result, as disclosed in Fig. 6, the disease activity index including clinical symptoms such as weight loss, diarrhea, and rectal bleeding increased in the colitis-induced group (DSS) administered with DSS compared to the normal group (NOR) that was not treated with anything, whereas these changed clinical symptoms were significantly reduced in the group administered with the extract of the present invention (LCHL, LCHH).

Example 6. Effect of administration of extract of gold leaf on reduction of intestinal permeability

The change in intestinal permeability following administration of the extract of the present invention was observed in a mouse model of colitis.

As a result, as disclosed in Fig. 7, the permeability of FD4 was significantly increased in the colitis-induced group (DSS) by DSS administration compared to the normal group (NOR) that was not treated with anything, and in contrast, the permeability of FD4 was significantly reduced in the groups (LCHL, LCHH) administered the extract of the present invention.

Example 7. Changes in colon lesions following administration of the extract of the goldenrod

In a mouse model of colitis, colonic lesions of mice with colitis were observed through an endoscope following administration of the extract of the present invention.

As a result, as disclosed in Fig. 8, the normal group (NOR) that was not treated with anything had normal colon tissue, whereas the colitis-induced group (DSS) administered with DSS showed a lot of inflammation and edema in the colon tissue. On the other hand, in the group administered with the extract of the present invention (LCHL, LCHH), it was confirmed that inflammation and edema in the colon tissue were reduced.

Claims (11)

A health functional food composition for preventing or improving any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, containing an extract of Lysimachia christinae as an active ingredient. A health functional food composition for preventing _or improving any _one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, characterized in that in claim 1, the extract is extracted using water, a lower alcohol of C 1 to C 4, or a mixture thereof. delete delete A health functional food composition for preventing or improving any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, characterized in that the composition is manufactured in any one formulation selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage, in claim 1. A pharmaceutical composition for the prevention or treatment of any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, containing an extract of Lysimachia christinae as an active ingredient. A pharmaceutical composition for the prevention or treatment of any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, characterized in that in claim 6, in addition to the effective ingredient, it further comprises a pharmaceutically acceptable carrier, excipient, or diluent. A pharmaceutical composition for the prevention or treatment of any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, characterized in that the composition is manufactured in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols in claim 6. A feed additive for preventing or improving any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, containing an extract of Lysimachia christinae as an active ingredient. A veterinary composition for the prevention or treatment of any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, containing an extract of Lysimachia christinae as an active ingredient. A herbal medicine composition for the prevention or treatment of any one inflammatory bowel disease selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), ischemic colitis, intestinal Behcet's disease, hemorrhagic rectal ulcer, and pouchitis, containing an extract of Lysimachia christinae as an active ingredient.